Sort   by:  
 Page size 
Imunopeptidomes promise novel surface markers as ideal targets for immunotherapies, but their characterization by mass spectrometry (MS) remains challenging. Until recently, cell numbers exceeding 1.0xE9 were needed for reasonably deep immunopeptidome surveys of at least 1,000 HLA ligands. Such limi...
ORGANISM(S): Homo sapiens (Human) 
2018-03-08 | PXD007860 | Pride
Cancer somatic mutations can generate neoantigens that distinguish malignant from normal cells. Such neoantigens have been implicated in response to immunotherapies including immune checkpoint blockade, yet their identification and validation remains challenging. Here we discover neoantigens in hu...
ORGANISM(S): Homo sapiens (Human) 
2017-03-27 | PXD004746 | Pride
Cancer somatic mutations can generate neoantigens that distinguish malignant from normal cells. Such neoantigens have been implicated in response to immunotherapies including immune checkpoint blockade, yet their identification and validation remains challenging. Here we discover neoantigens in huma...
ORGANISM(S): Homo sapiens (Human) 
2017-03-27 | PXD005704 | Pride
Sort   by:  
 Page size